Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.

Article  PubMed  Google Scholar 

Meifang W, Ying W, Wen C, Kaizu X, Meiyan S, Liming L. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials. Heart Fail Rev. 2024;29(2):305–20.

Article  PubMed  Google Scholar 

Verma AK, da Silva JH, Kuhl DR. Diuretic Effects of Subcutaneous Furosemide in Human Volunteers: A Randomized Pilot Study. Ann Pharmacother. 2004;38(4):544–9.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.

Article  Google Scholar 

Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: 3rd Symposium on Systematic Reviews: Beyond the Basics, Oxford, UK, 3–5 July 2000 [Internet]. 2000 [cited 2024 Apr 30]. Available from: https://cir.nii.ac.jp/crid/1573950400960524672

Bensimhon D, Weintraub WS, Peacock WF, Alexy T, McLean D, Haas D, et al. Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study. Future Cardiol. 2023;19(8):385–96.

Article  CAS  PubMed  Google Scholar 

Bensimhon D, Udelson J, Alexy T, Luepke K, Goodwin M, Kamineni P, et al. Analysis Of Subcutaneous Furosemide Dosing Patterns And Impact On SCr And K+ In The Freedom-HF And AT HOME Studies. J Card Fail. 2024;30(1):186.

Article  Google Scholar 

Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, et al. Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. JACC Heart Fail. 2018;6(1):65–70.

Article  PubMed  Google Scholar 

Galindo-Ocaña J, Romero-Mena J, Castillo-Ferrando JR, Aguilera-González C, Bernabeu-Wittel M, Ollero-Baturone M. Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure. BMJ Support Palliat Care. 2013;3(1):7–9.

Article  PubMed  Google Scholar 

Austin J, Hockey D, Williams WR, Hutchison S. Assessing parenteral diuretic treatment of decompensated heart failure in the community. Br J Community Nurs. 2013;11(528):530–4.

CAS  Google Scholar 

Birch F, Boam E, Parsons S, Ghosh J, Johnson MJ. Subcutaneous furosemide in advanced heart failure: service improvement project. BMJ Support Palliat Care. 2023;13(1):112–6.

Article  PubMed  Google Scholar 

Brown A, Robson J, Armstrong L, Matthews I, Runnett C, Thomas H. Use of community-based subcutaneous furosemide in advanced heart failure: experience of a new service in the north-east of England. Future Healthc J. 2019;6(Suppl 1):19.

Article  PubMed  PubMed Central  Google Scholar 

Civera J, de la Espriella R, Heredia R, Miñana G, Santas E, Conesa A, et al. Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: a Real-World Study. J Cardiovasc Transl Res. 2022;15(3):644–52.

Article  PubMed  Google Scholar 

De Boer RA, Ter MJ, Damman K, Muntendam P, Sica DA, Van VD, et al. Pharmacokinetic and pharmacodynamic response to oral and subcutaneous furosemide administration: first experiences with a novel buffered furosemide formulation in patients with chronic heart failure. J Am Coll Cardiol. 2016;67(13):1474–1474.

Article  Google Scholar 

Felker GM, Redfield MM, Mentz RJ, Dunlap ME, Lewis GD, Smith AL, et al. Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies. J Card Fail. 2019;25(8):S75.

Article  Google Scholar 

López-Vilella R, I SL, I HT, E MB, J NV, V DT, et al. Administration of Subcutaneous Furosemide in Elastomeric Pump vs. Oral Solution for the Treatment of Diuretic Refractory Congestion. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2021;28(6). Available from: https://pubmed.ncbi.nlm.nih.gov/34596886/.

Lozano Bahamonde A, Escolar Pérez V, Laskibar Asua A, Rodríguez Rodríguez M, Murga EN. Subcutaneous furosemide in patients with refractory heart failure. BMJ Support Palliat Care. 2018;8(3):354–5.

Article  PubMed  Google Scholar 

Mohr J, Myers R, Udelson JE, Bensimhon D, Russell SD. Effect of a Single Subcutaneous Infusion of Furosemide Compared with Intravenous Bolus on Vital Signs in Patients with Heart Failure. J Card Fail. 2018;24(8):S15–6.

Ojeifo O, Russell S, Okwuosa I, Almansa J, Cuomo K, Cummings A. Subcutaneous Versus Intravenous Furosemide in the Johns Hopkins Heart Failure Bridge Clinic. J Card Fail. 2016;22(8):S81.

Article  Google Scholar 

Osmanska J, Brooksbank K, Docherty KF, Robertson S, Wetherall K, McConnachie A, et al. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. Eur Heart J Cardiovasc Pharmacother. 2024;10(1):35–44.

Article  PubMed  Google Scholar 

Sica DD, Muntendam P, DeBoer RA, Pitt B. Pharmacokinetic and Pharmacodynamic Response after Subcutaneous Administration of a Novel Furosemide Formulation. J Card Fail. 2016;22(8):S11.

Article  Google Scholar 

Sica DA, Muntendam P, Myers RL, Ter Maaten JM, Sale ME, de Boer RA, et al. Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution. JACC Basic Transl Sci. 2018;3(1):25–34.

Article  PubMed  PubMed Central  Google Scholar 

Afari ME, Lemoine J, Michaelian M, Papafilippaki A, Tsao L. Evaluation of the clinical utility of a novel formulation of furosemide delivered subcutaneously in patients presenting with early signs of fluid overload. J Am Coll Cardiol. 2020;75(11):950–50.

Article  Google Scholar 

Zatarain-Nicolás E, López-Díaz J, de la Fuente-Galán L, García-Pardo H, Recio-Platero A, San Román-Calvar JA. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience. Rev Espanola Cardiol Engl Ed. 2013;66(12):1002–4.

Article  Google Scholar 

Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422–32.

Article  PubMed  PubMed Central  Google Scholar 

Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant Therapy: Heparin. Circulation. 2001;103(24):2994–3018.

Article  CAS  PubMed  Google Scholar 

Dahiya G, Bensimhon D, Goodwin MM, Mohr JF, Alexy T. From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion. Struct Heart. 2022;6(4): 100076.

Article  PubMed  PubMed Central  Google Scholar 

Schipper JH, Steven D, Lüker J, Wörmann J, van den Bruck JH, Filipovic K, et al. Comparison of pulsed field ablation and cryoballoon ablation for pulmonary vein isolation. J Cardiovasc Electrophysiol. 2023;34(10):2019–26.

Article  PubMed  Google Scholar 

Makadia S, Simmons T, Augustine S, Kovell L, Harris C, Chibungu A, et al. The Diuresis Clinic: A New Paradigm for the Treatment of Mild Decompensated Heart Failure. Am J Med. 2015;128(5):527–31.

Article  PubMed  Google Scholar 

Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, et al. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit. JACC Heart Fail. 2016;4(1):1–8.

Article  PubMed  Google Scholar 

Beattie JM, Johnson MJ. Subcutaneous furosemide in advanced heart failure: has clinical practice run ahead of the evidence base? BMJ Support Palliat Care. 2012;2(1):5–6.

Article  PubMed  Google Scholar 

Hamo CE, Abdelmoneim SS, Han SY, Chandy E, Muntean C, Khan SA, et al. OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST). PLoS ONE. 2021;16(6): e0253014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601–9.

Article  CAS  PubMed  Google Scholar 

Gottlieb SS, Khatta M, Wentworth D, Roffman D, Fisher ML, Kramer WG. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. Am J Med. 1998;104(6):533–8.

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Fonarow GC, Opsha Y, Sandhu AT, Sweitzer NK, Warraich HJ, et al. Economic Issues in Heart Failure in the United States. J Card Fail. 2022;28(3):453–66.

Article  PubMed  PubMed Central  Google Scholar 

Mazzoldi C, Aspidi F, Romito G. Dermatologic adverse effect of subcutaneous furosemide administration in a cat. Open Vet J. 2023;13(8):1027–31.

Article